Aprea Therapeutics Company Insiders

Aprea Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.419) % which means that it has lost $0.419 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7472) %, meaning that it created substantial loss on money invested by shareholders. Aprea Therapeutics' management efficiency ratios could be used to measure how well Aprea Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of February 17, 2026, Return On Tangible Assets is expected to decline to -0.65. In addition to that, Return On Capital Employed is expected to decline to -0.84. At present, Aprea Therapeutics' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 340.1 K, whereas Other Assets are forecasted to decline to about 32.1 K. The current year's Common Stock Shares Outstanding is expected to grow to about 6.7 M, whereas Net Loss is projected to grow to (96.3 M). Aprea Therapeutics shows significant amount of outstanding shares owned by insiders and institutional investors . Some institutional investors establish a significant position in stocks such as Aprea Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Aprea Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Aprea Therapeutics Workforce Comparison

Aprea Therapeutics Insider Trading

Aprea Therapeutics Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Aprea Therapeutics often depends on how effective the management is. Aprea Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aprea management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aprea management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of Aprea Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aprea Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Aprea Therapeutics' management manipulating its earnings.

When running Aprea Therapeutics' price analysis, check to measure Aprea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aprea Therapeutics is operating at the current time. Most of Aprea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aprea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aprea Therapeutics' price. Additionally, you may evaluate how the addition of Aprea Therapeutics to your portfolios can decrease your overall portfolio volatility.